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Abstract 32 
Attenuated poxvirus vectors expressing HIV-1 antigens are considered promising 33 
HIV/AIDS vaccine candidates. Here we described the nature of T cell immune 34 
responses induced in healthy volunteers participating in a phase I clinical trial in Spain 35 
after intramuscular administration of three doses of the recombinant MVA-B expressing 36 
monomeric gp120 and the fused Gag-Pol-Nef (GPN) polyprotein of clade B. The 37 
majority (92.3%) of the volunteers immunized had a positive specific T cell response at 38 
any time post-vaccination as detected by IFN-γ ICS assay. The CD4+ T cell responses 39 
were predominantly Env directed, whereas the CD8+ T cell responses were similarly 40 
distributed against Env, Gag and GPN. The proportion of responders after two doses of 41 
MVA-B was similar to that obtained after the third dose of MVA-B vaccination and the 42 
responses were sustained (84.6% at week 48). Vaccine-induced CD8+ T cells to HIV-1 43 
antigens after one year were polyfunctional and mainly distributed within the effector 44 
memory (TEM) and terminally differentiated effector memory (TEMRA) T cell 45 
populations. Anti-vector T cell responses were mostly induced by CD8+ T cells, highly 46 
polyfunctional and of TEMRA phenotype. These findings demonstrate that the poxvirus 47 
MVA-B vaccine candidate given alone is highly immunogenic, inducing broad, 48 
polyfunctional and long-lasting CD4 and CD8 T cell responses to HIV-1 antigens, with 49 
preference for TEM. Thus, on the basis of the immune profile of MVA-B in humans, 50 
this immunogen can be considered as promising HIV/AIDS vaccine candidate. 51 
52 
Introduction 53 
Since 1981, more than 25 million people have died of Acquired Immune Deficiency 54 
Syndrome (AIDS), a dramatic pandemic caused by the Human Immunodeficiency Virus 55 
(HIV). In 2009 the UNAIDS estimates that 33.4 million people now live with HIV-1 56 
infection. Although anti-retroviral therapy (ART) can suppress viral replication 57 
increasing life expectancy among those people infected, it cannot cure the infection. 58 
Moreover, affordable ART coverage in resource-poor, HIV-1 endemic regions is a 59 
daunting global health problem. For these reasons the development of a safe and 60 
efficacious vaccine represents the best long-term solution to ending the HIV-1 61 
epidemic. 62 
There have been strong proponents of either antibodies or T cells alone as the most 63 
effective strategy that should be followed to prevent HIV-1 infection. However, the 64 
consensus view now is that a highly effective HIV/AIDS vaccine will need to elicit 65 
coordinated B cell, CD4+ and CD8+ T cell responses (27).  66 
More than 30 HIV/AIDS vaccine candidates, whose prototypes have elicited varying 67 
degrees of protective responses in nonhuman primate models have advanced to human 68 
clinical trials, alone or in combinations (25, 36). These include replication-competent or 69 
incompetent viral vectors (poxvirus, adenovirus, alphavirus, adeno-associated virus) 70 
containing HIV-1 gene inserts, HIV-1 virus-like particles, HIV-1 DNA plasmids and 71 
soluble HIV-1 proteins and peptides, with or without adjuvant formulations. Among the 72 
candidate regimens that have been extended to large-scale international phase IIb or III 73 
studies only the RV144 trial, that evaluated a recombinant canarypox-HIV-1 vector 74 
prime and recombinant HIV-1 envelope gp120 subunit protein plus alum boost in 75 
Thailand, demonstrated low-level efficacy (31%) in reducing HIV-1 infection rates (35). 76 
These clinical findings provided for the first time evidence that an HIV/AIDS vaccine 77 
can prevent HIV-1 infection and highlight that poxvirus vectors should be considered as 78 
one of the future HIV/AIDS vaccine candidate vectors.  79 
Among the poxviruses, the attenuated Modified Vaccinia Ankara (MVA) strain has 80 
received great attention in terms of vaccine development for prevention and therapeutic 81 
purposes (12). The main advantage of MVA is its safety record. Despite its limited 82 
replication in human and most mammalian cell types, MVA provides a high level of 83 
gene expression and triggers strong immune responses when delivering foreign antigens 84 
in animals and humans (12, 30, 39). In fact, in the last years several clinical trials have 85 
been conducted using MVA-based vaccines in both healthy and HIV-1-infected human 86 
volunteers (10, 22, 24, 38, 40). These studies demonstrated that the recombinant vectors 87 
based on MVA are safe and well tolerated and are able to induce HIV-1-specific 88 
immune responses when administered alone or in combination with other vectors. 89 
However, the magnitude, response rates and durability in immunization regimens using 90 
homologous vectors were modest. These observations highlight that more efficient 91 
MVA vectors with the ability to enhance the magnitude, breadth, polyfunctionality and 92 
durability of the immune responses to HIV-1 antigens are desirable. This is particularly 93 
relevant if a single immunogen is target for mass vaccination purposes, to simplify the 94 
immunization protocol and reduce manufacture burden. 95 
Here we have characterized the immunogenicity of the recombinant MVA-B, 96 
expressing Env, Gag, Pol and Nef HIV-1 antigens from clade B, in healthy volunteers 97 
enrolled in the RISVAC02 phase I clinical trial. The construction details and preclinical 98 
setting of this vaccine were published earlier (8, 11). We specifically addressed the 99 
breadth, phenotype, polyfunctionality and longevity of the vaccine elicited immune 100 
responses in order to provide insights into the immune protective potential of 101 
homologous MVA-B vaccine regimen in humans.  102 
103 
Materials and Methods 104 
MVA-B vaccine 105 
The generation of MVA-B vector was previously described (11). It expresses 106 
simultaneously and under the same synthetic early/late viral promoter, monomeric 107 
gp120 as a cell released product and Gag-Pol-Nef (GPN) as an intracellular polyprotein 108 
of 160 KDa. gp120 Env protein comes from the HIV-1 primary isolate BX08. Gag-Pol-109 
Nef is a fusion protein of 1326 amino acids composed of gag, pol and nef ORFs from 110 
HIV-1 clone IIIB, that has been modified to enhance its immunogenicity and for safety 111 
by removing undesirable domains. In both cases, the codon usage was adapted to highly 112 
express human genes. The good manufacturing production (GMP) clinical lots of 113 
MVA-B were produced by IDT (Germany) and kindly provided by EuroVacc. MVA-B 114 
was genetically stable, even when grown and purified at large scale under GMP 115 
conditions as previously described (11). 116 
 117 
Study design 118 
The RISVAC02 study was approved by the institutional ethical review board and by the 119 
Spanish Regulatory Authorities (Government identifier: NCT00679497). The study was 120 
explained to all patients in detail, and all signed written informed consent documents. A 121 
total of 30 HIV-1 negative, vaccinia-naïve volunteers, at two clinical sites in Madrid  122 
(HGM) and Barcelona (HC) were randomly allocated to receive 3 x 1 ml injections of 123 
MVA-B (108 pfu/dose) (n=24) or placebo (n=6) by intramuscular route at weeks 0, 4 124 
and 16. The duration of participant follow up was 48 weeks.  125 
 126 
Synthetic peptides  127 
All peptides used in this study were HPLC purified (>80% purity) and provided by 128 
EuroVacc. Overlapping peptides (15 mers with 11 amino acids overlap; n=450) covered 129 
the entire Env, Gag, Pol and Nef regions from clade B included in MVA-B. The 130 
BX08gp120 protein (494 aa) was spanned by the Env-1 (aa: 1-251; 60 peptides) and Env-131 
2 (aa: 241-494; 61 peptides) pools. The Gag-Pol-Nef fusion protein (1326 aa) was 132 
spanned by the following pools: Gag-1 (aa: 1-231; 55 peptides), Gag-2 (aa: 221-431; 50 133 
peptides), GPN-1 (aa: 421-655; 56 peptides), GPN-2 (aa: 645-879; 56 peptides), GPN-3 134 
(aa: 869-1103; 56 peptides) and GPN-4 (aa: 1093-1326; 56 peptides). For 135 
immunological analyses we grouped the pools as follows: Env pool (Env-1+Env-2); 136 
Gag pool (Gag-1+Gag-2) and GPN pool (GPN-1+GPN-2+GPN-3+GPN-4).  137 
 138 
Cell preparation  139 
Whole blood samples for analyses of the immune responses were collected in cell 140 
preparation tubes (CPT Vacutainer tubes; BD) and processed within 6 hours, in 141 
accordance with manufacturer´s instructions. The yield and viability of peripheral blood 142 
mononuclear cells (PBMCs) were determined by trypan blue staining. Fresh PBMCs 143 
were used for the immunological analyses described in this study. The remaining cells 144 
were cryopreserved. 145 
 146 
Flow cytometry analyses  147 
Fresh PBMCs (1–2 × 106) were stimulated during 6 hours in complete RPMI 1640 148 
media containing 1 μl/ml Golgiplug (BD Biosciences) and 5 μg/ml of the different HIV-149 
1 peptide pools. When the anti-vaccinia response was assayed, the PBMCs were 150 
stimulated during 6 hours in complete media containing 1 μl/ml Golgiplug (BD 151 
Biosciences) and autologous cells infected with MVA at 2 pfu/cell in a ratio 10:1. For 152 
functional analyses the following fluorochromes-conjugated antibodies were used: 153 
CD3-AmCyan; CD4-Alexa 700; CD8-PerCPCy5.5; IFN-γ-V450 or -PECy7; IL-2-APC; 154 
TNF-α-PECy7 and MIP1β-PE. In addition, for phenotypic analyses the following 155 
antibodies were used: CCR7-PE and CD45RA-FITC. All antibodies were from BD 156 
Biosciences. At the end of the stimulation period, cells were stained for the surface 157 
markers, permeabilized (Cytofix/Cytoperm kit; BD Biosciences) and stained 158 
intracellularly using the appropriate fluorochromes. Cells were collected on an LSR II 159 
flow cytometer (BD Immunocytometry Systems). Analyses of the data were performed 160 
using the FlowJo software version 8.5.3 (Tree Star, Ashland, OR). The number of 161 
lymphocyte-gated events ranged between 105 and 106. After gating, Boolean 162 
combinations of single functional gates were then created using FlowJo software to 163 
determine the frequency of each response based on all possible combinations of 164 
cytokine expression or all possible combinations of differentiation marker expression. 165 
Background responses detected in negative control tubes were substracted from those 166 
detected in stimulated samples for every specific functional combination.  167 
 168 
Data analysis and statistics 169 
To correct measurements of the medium response (RPMI) we used a novel statistical 170 
approach previously described (8, 29). An ICS was considered positive if the 171 
percentages of cytokine+ cells in the stimulated samples were 3 times over the values 172 
obtained in the unstimulated controls and if the background-substracted magnitudes 173 
were higher than 0.02%. The background for the different cytokines in the unstimulated 174 
controls never exceeded 0.015%. Each participant was classified as a responder if there 175 
was at least one positive IFN-γ ICS response against any of the HIV-1 peptide pools at 176 
weeks 6, 18 or 48 and as a nonresponder if responses at these weeks were all negative.  177 
The magnitude of the ICS responses and other continuous variables were compared 178 
between groups using the nonparametric tests Wilcoxon rank sum test and Mann-179 
Whitney U test. The differences among cumulative proportions have been tested by 180 
comparing two binomial distributions as described in (41) (implemented by the R 181 
function prop. test). For correlation analysis between variables the Pearson´s correlation 182 
coefficient test was used. 183 
The data analysis program, Simplified Presentation of Incredibly Complex Evaluations 184 
(SPICE, version 4.1.5, Mario Roederer, Vaccine Research Center, NIAID, NIH), was 185 
used to analyze and generate graphical representations of T cell responses detected by 186 
polychromatic flow cytometry. All values used for analyzing proportionate 187 
representation of responses are background-substracted. 188 
189 
Results 190 
Study design 191 
The main objective of this study was to characterize the magnitude, breadth, phenotype, 192 
function and durability of the T cell responses induced by the single recombinant MVA-193 
B administered in three doses in human healthy volunteers enrolled in the RISVAC02 194 
phase I clinical trial in Spain.The MVA-B vaccine is a non-replicating viral vector in 195 
human cells that expresses simultaneously the gp120 Env protein from the BX08 HIV-1 196 
isolate as a cell released product and Gag-Pol-Nef (GPN) from the IIIB HIV-1 isolate as 197 
an intracellular polyprotein (11). GPN has been engineered by the removal of 198 
immunosuppressed sequences and to prevent virus-like particles (VLP) formation. A 199 
total of 30 healthy, HIV-1 negative volunteers, naïve for smallpox vaccine, were 200 
enrolled. The study was randomized and double-blinded with respect to active vaccine 201 
or placebo. The participants received 3 x 1ml injections of MVA-B (108 pfu/dose) 202 
intramuscularly in the deltoid at weeks 0, 4 and 16. The immune responses were 203 
evaluated at weeks 6, 18 and 48 by polychromatic intracellular cytokine staining (ICS) 204 
(Figure 1A). This assay was done in 16 volunteers due to rapid availability of freshly 205 
isolated peripheral blood mononuclear cells (PBMCs) to ensure no loss of functional 206 
activity of T cells.  207 
Analyses of the demographics of the trial population and of the safety of the vaccine 208 
will be described elsewhere (García, F et al., submitted). No related serious adverse 209 
events occurred during the study indicating that MVA-B was safe and well tolerated. 210 
 211 
Vaccine-induced T cell responses 212 
Vaccine-induced T cell responses were assessed in 16 volunteers by ICS assay after the 213 
stimulation of freshly isolated PBMCs with a panel of 450 HIV-1 peptides (15 mers 214 
overlapping by 11 amino acids) grouped in three pools: Env (121 peptides), Gag (105 215 
peptides) and GPN (224 peptides). The peptides encompassed the Env, Gag, Pol, and 216 
Nef proteins of HIV-1 and were designed based on the sequence of the immunogens 217 
expressed by MVA-B. 218 
The response rates at weeks 6, 18 and 48 were determined for each T cell population 219 
based on the percentage of antigen-specific IFN-γ+ cells. Cumulative analysis of the 220 
data demonstrated that MVA-B induced HIV-1-specific T cell responses that were 221 
balanced and significantly different to those determined in the placebo group (p=0.04) 222 
(Table 1). CD4+ and CD8+ T cell responses to any HIV-1 peptide pool at any time 223 
post-vaccination were detected in 69.2% (9/13) and 92.3% (12/13) of the vaccines, 224 
respectively. The CD4+ T cell responses were predominantly Env directed (Env: 69.2% 225 
vs Gag: 15.4% and GPN: 7.7%) whereas the CD8+ T cell responses were similarly 226 
distributed against the three peptide pools (Env: 61.5%, Gag: 69,2% and GPN: 69.2%). 227 
The assessment of vaccine-induced T cell responses at different time points, determined 228 
as the rate of CD4+ and/or CD8+ responses to any HIV-1 antigen, indicated that the 229 
proportion of responders after 2 doses of MVA-B (W6) was similar to that obtained 230 
after the third dose of MVA-B vaccination (W18) (75% vs 69.2%) and was sustained by 231 
32 weeks after the last immunization (84.6% at W48) (Figure 1B). The mean values for 232 
the total HIV-1 responses (Env+Gag+GPN) in each T cell population are shown in 233 
Figure 1C. For CD4+ T cells both the magnitude and response rates peaked after 2 234 
MVA-B doses, declining with time. The response rates to any antigen decreased from 235 
58.3% at W6 to 23.1% at W18 and to 38.5% at W48 (Table 1). For CD8+ T cells both 236 
magnitude and response rates were higher than for CD4+ T cells, specially at weeks 18 237 
and 48. The magnitude of the responses remained similar during the study as well as the 238 
response rates to any antigen (50% at W6; 61.5% at W18 and 69.2% at W48) (Table 1). 239 
There was no significant correlation between the magnitude of the response for CD4+ 240 
and CD8+ T cells in individuals. 241 
The CD4+ T cell response was essentially directed against 1 HIV-1 peptide pool (Env) 242 
at all time points assayed, with occasional recognition of 2 antigens (Env and Gag), 243 
whereas the CD8+ T cell response was broad and evenly distributed to 1, 2 or 3 HIV-1 244 
peptide pools (Figure 1D). 245 
The cross-sectional responsiveness per antigen showed that Env response was mediated 246 
by both CD4 and CD8 T cell subsets whereas the Gag and GPN responses were mainly 247 
mediated by the CD8 T cell population (Figure 1E).  248 
 249 
Functional profile of vaccine-induced CD4 and CD8 T cell responses 250 
The profile of vaccine-induced CD4 and CD8 T cell responses was analysed in those 251 
volunteers with IFN-γ+ ICS responses. The polychromatic ICS assays were performed 252 
on fresh PBMCs at 2 weeks after both the second (W6) and third dose (W18) of MVA-253 
B vaccine. The panel of T cell functions analyzed included IL-2, TNF-α, MIP1β and 254 
IFN-γ secretion. For each subpopulation the background, as detected in the unstimulated 255 
control sample, was substracted. Only responses exceeding a predefined threshold level 256 
after background substraction were considered. 257 
The mean values for the total responses (Env+Gag+GPN) in each T cell population 258 
considering the frequencies of all the cytokines are represented in Figure 2A. The 259 
magnitudes of the total HIV-1-specific responses were similar for both populations at 260 
the two time points. Among the cytokine producing CD8+ T cells, IFN-γ and MIP1β 261 
predominate at both weeks 6 and 18 whereas no single cytokine prevail in the CD4+ T 262 
cells at any time assayed (Figure 2B). Representative functional profiles of vaccine-263 
induced CD4 and CD8 T cell responses were shown for one of the responders at week 264 
18 (Figure S1). 265 
The quality of a T cell response can be characterized in part by the pattern of cytokine 266 
production. On the basis of the analysis of IL-2, TNF-α, MIP1β and IFN-γ secretion, 15 267 
distinct HIV-1-specific CD4+ and CD8+ T cell populations were identified (Figure 3). 268 
Vaccine-induced CD4+ T cell responses at weeks 6 and 18 were mainly represented by 269 
cells expressing 1 function, although about 25% of CD4+ T cells exhibit two or three 270 
functions. In contrast to CD4+ T cells, vaccine-induced CD8+ T cells were more 271 
polyfunctional, with about 45% of vaccine-induced HIV-1-specific CD8+ T cells 272 
exhibiting more than one function (Figure 3). In both subsets there were no changes in 273 
the polyfunctional profile after the third dose of MVA-B.  274 
To define if polyfunctionality is a feature of an individual or of responses to particular 275 
antigens, we performed a two-way ANOVA (response as a function of the patient and 276 
the antigen) of the responses for CD8+ and CD4+ T cells after 2 (W6) and 3 doses 277 
(W18). We found that all patients responded similarly (except one individual who is 278 
particularly polyfunctional responsive for CD8+ after 2 doses). At week 6 we found 279 
significant differences (p <0.05) between the polyfunctional response of CD8+ T cells 280 
to Env, Gag and GPN versus the polyfunctional response to MVA. Similarly, the 281 
polyfunctional response of CD4+ T cells to Env was significantly larger than that to 282 
GPN. The rest of the responses were not significantly different. At week 18 we did not 283 
find any difference between the polyfunctional responses of individuals and antigens at 284 
the level of CD8+ T cells. Moreover, when we determined if the magnitude or breadth 285 
of the response correlate with the polyfunctionality we only found a positive correlation 286 
(0.78) between breadth and CD8+ polyfunctionality after 2 doses (W6). Otherwise, 287 
these variables are not correlated (with Pearson's correlation coefficient test). 288 
 289 
Phenotypic profile of long-lived memory HIV-1-specific T cell responses 290 
Phenotypic analysis of long-lived memory vaccine-induced T cell responses was carried 291 
out at 32 weeks after the last MVA-B immunization (W48) by polychromatic ICS 292 
assay. Fresh PBMCs were stimulated with the HIV-1 peptide pools Env, Gag and GPN 293 
for 6 hours and stained with specific antibodies to identify T cell lineage (CD3, CD4 294 
and CD8), responding cells (IL-2 and IFN-γ) as well as memory stages (CD45RA and 295 
CCR7). 296 
At this time point the HIV-1-specific response was mainly mediated by CD8+ T cells, 297 
although in 3 out of 11 responders (27.3%) was mediated by both CD4+ and CD8+ T 298 
cells. 55.6% of the responders at W48 had specific-CD8+ T cells against 2 or 3 pools, 299 
correlating with the individuals that secrete more IFN-γ (p<0.05  ). 300 
Since previous studies have shown that CD45RA and CCR7 define functionally distinct 301 
populations of memory antigen-specific T cells (4, 19, 37), we characterized the 302 
differentiation stages of the responding CD4 and CD8 T cells into central memory 303 
(TCM: CD45RA−CCR7+), effector memory (TEM: CD45RA−CCR7−) or terminally 304 
differentiated effector memory (TEMRA: CD45RA+CCR7-) populations. For each 305 
vaccinee we summed the totality (single IL-2 plus dual IL-2/IFN-γ plus single IFN-γ) of 306 
Env+Gag+GPN specific T cell responses and determined for CD4 and CD8 T cell 307 
subsets the percentages of the specific responses with phenotype TCM, TEM or 308 
TEMRA (Figure 4). The HIV-1-specific CD4+ T cell responses were mainly distributed 309 
within the TCM and TEM cell populations whereas the CD8+ T cell responses were 310 
mainly distributed within the TEM and TEMRA cell populations (Figure 4A). In both 311 
CD4 and CD8 T cell subsets the higher numbers of cytokine secreting cells were found 312 
within the TEM cell population. Figure 4B shows representative phenotypic profiles of 313 
long-lived memory HIV-1-specific T cells in one of the volunteers.  314 
 315 
Anti-vector T cell responses 316 
Vaccine-induced anti-vector T cell responses were assessed by ICS assay after the 317 
stimulation of freshly isolated PBMCs with autologous cells infected with MVA. The 318 
response rates at weeks 6, 18 and 48 were determined for each T cell population based 319 
on the percentages of MVA-specific IFN-γ+ cells following the same criteria described 320 
above. The analysis of anti-vector T cells responses at different time points, determined 321 
as the rate of CD4 and/or CD8+ responses to MVA-infected cells, indicated that the 322 
proportion of responders after 2 doses of MVA-B (W6) was similar to the obtained after 323 
the third MVA-B vaccination (W18) (83.3% vs 84.6%) and remained unchanged over 324 
time (91.7% at W48) (Figure S2A). There was not correlation between vector and HIV-325 
1 antigen responses. None of the placebo recipients had a positive response against the 326 
vector. The responses were mostly induced by the CD8 T cells (Figure 5A) and were 327 
highly polyfunctional, with about 70% of MVA-specific CD8+ T cells displaying more 328 
than one function (Figure 5B). The magnitude and polyfunctionality of anti-vector CD8 329 
T cell responses were maintained after the third dose of MVA-B. Representative 330 
functional profiles of the anti-MVA responses in one of the volunteers at week 18 are 331 
shown in Figure S2B. Although anti-vector CD8+ T cell responses appeared to be more 332 
polyfunctional than responses to the HIV-1 antigens, we have to take into consideration 333 
that the different assay system used (one stimulated with peptide pools, the other with 334 
virus-infected cells) might influence the result and do not allow the direct comparison 335 
between the polyfunctional degree against the vector and against the HIV-1 antigens. 336 
To define if strong responses to the vector at earlier times reduce the benefit of boosting 337 
for the HIV-1 antigens, we analyzed using Pearson's correlation coefficient test if the 338 
anti-vector response at week 6 affect the anti-HIV-1 response at week 18, and we found 339 
that strong responses to the vector at earlier times do not reduce the benefit of boosting 340 
for the HIV-1 antigens (0.348). 341 
At week 48, the totality (single IL-2 plus dual IL-2/IFN-γ plus single IFN-γ) of MVA 342 
specific CD4+ T responses were mainly distributed within the TEM cell population 343 
whereas the CD8+ T cell responses were mainly distributed within the TEMRA cell 344 
population (Figure 5C). Representative phenotypic profiles of long-lived memory 345 
MVA-specific T cells are shown in one of the volunteers (Figure S2C).  346 
347 
Discussion 348 
At present it remains unclear which elements of the immune system need to be 349 
stimulated to provide protection against HIV-1 infection and to improve viral control in 350 
already HIV-1 infected individuals. For this reason, HIV/AIDS vaccine development is 351 
currently directed towards the quantitative and qualitative improvements of vaccine 352 
induced immune responses through the use of novel vectors administered either alone or 353 
in prime-boost heterologous combination. The modest efficacy and low-level immune 354 
responses of the RV144 Thai phase III trial based on the poxvirus vector ALVAC in 355 
combination with the protein gp120 (35), suggest that improved poxvirus vectors may 356 
be effective components of a realistic strategy for vaccination against HIV-1 infection.  357 
We have previously described the generation and characterization of the MVA-B 358 
vaccine candidate against HIV/AIDS (11). MVA-B used alone, or in combination with 359 
DNA vectors expressing the same HIV-1 antigens, was able to induce in mice robust, 360 
polyfunctional and durable T cell HIV-1-specific responses (8, 11). In macaques, a 361 
similar MVA construct expressing Env (gp120 from SHIV89.6P) and Gag-Pol-Nef (from 362 
SIVmac239) induced strong specific CD4+ and CD8+ T cell immune responses with a 363 
bias for CD8+, and high protection after challenge with SHIV89.6P (28). Furthermore,  364 
expression of HIV-1 antigens from MVA-B selectively induced in human monocyte-365 
derived dendritic cells (moDCs) the expression of different cellular genes that might act 366 
as regulators of immune responses to HIV-1 antigens (14), and MVA-B-infected 367 
moDCs co-cultured with autologous T lymphocytes induced a highly functional HIV-1-368 
specific CD8+ T cell response including proliferation, secretion of IFN-γ, IL-2, TNF-α, 369 
MIP1β, MIP1α, RANTES and IL-6, and strong cytotoxic activity against autologous 370 
HIV-1-infected CD4+ T lymphocytes (2). Based on these previous results, MVA-B was 371 
approved in Spain for a phase I clinical trial in healthy volunteers (RISVAC02).  372 
The primary aim of this study was to characterize in detail the magnitude, breadth 373 
phenotype, function and type of memory T cell responses induced by the recombinant 374 
MVA-B in participants enrolled in the RISVAC02 clinical trial. The availability of fresh 375 
PBMCs from 16 volunteers obtained at different times post-immunization made it 376 
possible to analyze directly the T cell profile in all of these samples, thus assuring 377 
minimal loss of T cell functions. The analysis of the vaccine-induced T cell responses 378 
was performed by polychromatic ICS assay from PBMCs stimulated with a panel of 379 
peptide pools encompassing Env, Gag, Pol, and Nef HIV-1 antigens from clade B 380 
included in the MVA-B vector. Although the IFN-γ ELISPOT is the best standardized 381 
assay used internationally for measuring HIV-1 vaccine induced immune responses (1, 382 
5, 13), it provided limited information on a spectrum of cytokine/chemokine profiles. 383 
To overcome the limitation of evaluating a single cytokine, novel techniques, as the 384 
polychromatic ICS assay, are becoming increasingly more stringent in assessing HIV-1-385 
specific immune responses in different clinical settings (3, 10, 16, 22). This assay 386 
provides simultaneous information on multiple markers measured at the single cell level 387 
allowing a detailed characterization of the vaccine specific T cell responses.  388 
Here we demonstrate that the vaccination regimen based on 3 doses of 108 pfu of MVA-389 
B given intramuscularly is highly immunogenic, induces high frequency of HIV-1-390 
specific CD4+ and CD8+ T cells which are polyfunctional and with broad IFN-γ ICS 391 
reactivity, and more importantly, this vaccine regimen induces long-lasting T cell 392 
immunity activating specific subset of memory T cell populations. The majority (12 out 393 
of 13, 92.3%) of the volunteers immunized with MVA-B had a positive HIV-1-specific 394 
T cell response at any time post-vaccination detected by IFN-γ ICS assay. While direct 395 
comparison of overall response rates between MVA recombinants tested in clinical 396 
trials has to be taken with caution due to differences in the HIV-1 expressing cassette of 397 
the vectors, simple comparison with other stand-alone MVA-based HIV-1 vaccine 398 
products revealed that MVA-B appears to be as good or even better immunogen than 399 
MVA-CMDR (84.6%) (3), more immunogenic than MVA62 (43%) (10) and 400 
substantially more immunogenic than MVA.HIVA (0%) (21, 32). Other studies using 401 
the same immunization regimen, but with higher doses of MVA products, had reported 402 
similar or even lower response rates than those reported here. The use of ADMVA (40) 403 
and TBC-M4 (34) at 2.5 fold higher doses than MVA-B gave response rates of 62% and 404 
100%, respectively. Furthermore, after a third dose of 109 pfu of MVA-HIV a response 405 
rate of 41.4% was reported (22). MVA-B was also more immunogenic than the related 406 
attenuated poxvirus vector NYVAC-C used in homologous combination (16, 26). 407 
Overall, the response rates assigned to MVA-B in comparison with other MVA-HIV 408 
related vaccines provided strong support for the potential benefit of this vector as an 409 
HIV/AIDS vaccine candidate.  410 
Considering the consensus that for an HIV/AIDS vaccine to be effective it should aim 411 
to trigger specific T cell immune responses with an immunogenic profile of high 412 
frequency of CD4+ and CD8+ T cells, polyfunctional and durable, the immunogenic 413 
characteristics of MVA-B described in this work fulfil these criteria. The HIV-1-414 
specific T cell responses induced by MVA-B vaccine were balanced, with CD4+ and 415 
CD8+ T cell responses detected in 69.2% and 92.3% of the vaccinees, respectively.  416 
The CD4+ T cell response peaked and then decline after the second dose of MVA-B 417 
and was directed almost entirely to Env, whereas the CD8+ T cell response slightly 418 
increases over time and was more evenly distributed between Env, Gag and GPN 419 
antigens. These results were in line with the preclinical evaluation of MVA-B in mice 420 
(8, 11) and also with the results obtained in macaques using an analogous MVA 421 
expressing gp120 from SHIV89.6P and Gag-Pol-Nef from SIVmac239 (28), but differed 422 
from studies by others that suggest that MVA-vectored constructs expressing multigenic 423 
products induced primarily a CD4+ T cell response (3, 10, 22). Using flow cytometry-424 
based assays, Currier et al. reported that Env antigen was consistently the predominant 425 
target of the cellular immune response, and CD4+ T cells were the most frequently 426 
detected responder cell type when using 108 pfu of MVA-CMDR (3). Using the 427 
MVA62 in homologous regimen it was reported a 2.4-fold excess of CD4+ over CD8+ 428 
T cells responses with strong bias towards Gag (10). More recently it was reported that 429 
after 3 doses of 109 pfu of MVA-HIV there was 3-fold excess of CD4+ over CD8+ 430 
responses, being the CD4+ T cell response more frequently directed at Gag than Env, 431 
and the CD8+ T cell response directed entirely at Env (22). The divergences observed 432 
between the studies described above and our study must be attributed to the delivery 433 
format and the nature of the HIV-1 antigens expressed by the different vaccine 434 
candidates. The MVA-CMDR and MVA62 share similar features. In both recombinants 435 
the truncated gp160 env gene was inserted into the deletion II, whereas the modified 436 
gag-pol gene was inserted into the deletion III. In addition, both viruses expressed the 437 
Env protein on the surface of the infected cells while Gag and Pol antigens are produced 438 
as noninfectious virus-like particles (VLPs) (6, 10). On the other hand, MVA-HIV 439 
represents a mix of two different MVA recombinants, one expressing the structural env 440 
and gag genes and the other expressing the regulatory tat, rev, nef and reverse 441 
transcriptase (RT) genes, all at different locus (22). Our MVA-B vaccine has inserted in 442 
the single viral TK locus the env and gag-pol-nef genes, and both are expressed in 443 
infected cells simultaneously, with the monomeric gp120 Env protein as a cell released 444 
product, and Gag-Pol-Nef (GPN) as an intracellular polyprotein. The better stimulation 445 
of CD4 T cells in the previous studies might be related with the preferential activation 446 
of the exogenous pathway of antigen presentation by secreted products as VLPs or Env 447 
protein. In fact, in our study almost all the vaccine-induced CD4+ T cell response was 448 
directed against Env. The MVA-B-induced T cell responses against Gag and GPN 449 
antigens were mainly mediated by CD8+ T cells and this might be related with the 450 
activation of the intrinsic pathway of antigen presentation by the Gag-Pol-Nef 451 
intracellular polyprotein. As we have reported, both the expression of gp120 and GPN 452 
by MVA-B on moDCs had an effect on host cellular functions. In fact, expression of 453 
HIV-1 proteins from moDCs infected with MVA-B induced the expression of 454 
cytokines, cytokine receptors, chemokine receptors, and molecules involved in antigen 455 
uptake and processing, including major histocompatibility complex (MHC) genes, 456 
whose products might act as regulators of immune responses to HIV-1 antigens (14). 457 
Moreover, MVA-B infection of moDCs stimulate strong HIV-1 immune response, 458 
mainly induced by CD8+ T cell proliferation together with high secretion of CD8+-459 
polyfunctional-related cytokines (2). Thus, the preferential induction of CD8+ T cells 460 
by MVA-B might be related to the intrinsic innate vector-effects on target cells. 461 
In addition to T cell responses, MVA-B also elicited strong and durable Env-specific 462 
humoral response. Binding antibodies against HIV-1 LAVgp160 were detected in 463 
45.8% of the volunteers after the second MVA-B dose, while nearly all recipients 464 
(95.8%) tested positive by ELISA after the third MVA-B dose. At 32 weeks after the 465 
last immunization 72.7% of the vaccinees had detectable levels of anti-Env antibodies 466 
(García, F et al., submitted). These results are comparable to the previous studies 467 
reported by Currier et al. (3) and Goepfert et al. (10)  in which the anti-Env antibody 468 
responses peaked after the third dose of MVA-CMDR (90%) and MVA62 (86%) 469 
respectively. 470 
In our vaccination scheme with MVA-B, the last boost was needed to enhance humoral 471 
HIV-1-specific responses in vaccinees, and might also be important for increasing and 472 
maintaining the anti-Gag and anti-GPN CD8+ T cell responses. The ICS data correlated 473 
with the immune responses detected by IFN-γ ELISPOT in all volunteers included in 474 
the RISVAC02 study, where at early times the higher responses were detected against 475 
Env and after the third dose of MVA-B these responses were against Gag and GPN 476 
(Garcia,F et al., submitted). Similar remarks were reported in the MVA62 study 477 
although the specific responses were lost 6 months after the last dose (10). The 478 
induction of Gag responses in vaccinees could be favourable for a vaccine since in the 479 
natural HIV-1 infection it has been reported that Gag-specific CD8+ T cell responses 480 
are associated with better control of HIV/AIDS disease in individuals with chronic 481 
HIV-1 infection (7, 9, 23). The HIV-1-specific CD4+ and CD8+T cell responses 482 
induced by MVA-B vaccine were polyfunctional and both T cells subsets maintained 483 
similar functional profiles after 2 or 3 doses of the MVA-B vaccine. In this regard 484 
several studies performed in the setting of HIV-1 infection have shown that 485 
polyfunctional T cell responses are associated with better clinical outcome and 486 
protection from disease progression (20, 31, 33).  487 
A critical component of the effectiveness of vaccines is their ability to induce long-488 
lasting immunity. Here we observed that 84.6% of volunteers have HIV-1-specific T 489 
cell responses at week 48. This response rate is higher than the reported in other studies 490 
using multigenic vaccines such as MVA-CMDR (about 60%) (3), MVA62 (8%) (10) or 491 
TBC-M4, that although reported 100% of responders after the third dose, point out that 492 
only few vaccinated individuals exhibited long lasting responses (34). The T cell 493 
responses at week 48 were balanced and do not differ with the response obtained 2 494 
weeks after the third booster. In our volunteers the vaccine-induced CD4+ T cell 495 
populations had mainly TCM (CD45RA−CCR7+) or TEM (CD45RA−CCR7−) 496 
phenotypes which correspond to cells with effector functions but also with the ability to 497 
secrete IL-2 and endowed with proliferation capacity (4, 17, 19, 37). In the case of 498 
CD8+ T cells the memory phenotypes were either TEM (CD45RA−CCR7−) or TEMRA 499 
(CD45RA+CCR7−). The presence of both memory populations at 8 months after the last 500 
vaccination is an important consideration since they have been implicated in the control 501 
of different virus infections. The presence of CD45RA+CCR7− CD8 T cells has been 502 
found in controlled chronic virus infections such as CMV and EBV (4, 18, 42), and a 503 
correlation between the percentage of this cell population and virus control has also 504 
been shown in HIV-1 infection (31). Moreover, it was recently described the relevance 505 
of the effector memory T cells on the early control of highly pathogenic SIV (15). 506 
As others (33), we observed that MVA-B vaccine also induced specific anti-vector 507 
immune responses mainly mediated by the CD8 T cells. The responses were highly 508 
polyfunctional, with about 70% of MVA-specific CD8+ T cells displaying more than 509 
one function. Significantly, the magnitude and polyfunctionality of anti-vector CD8+ T 510 
cell responses were maintained after the third dose of MVA-B and were durable, with a 511 
phenotype related with advanced stages of differentiation. The anti-vector memory 512 
responses were predominantly of TEM phenotype for CD4+ T cells and of TEMRA for 513 
CD8+ T cells. 514 
In conclusion, this study revealed a number of significant findings on the immune 515 
profile of the MVA-B vector as an HIV/AIDS vaccine based on ICS data from human 516 
PBMCs. First, the vector MVA-B given alone is highly immunogenic as over 90% 517 
recipients responded to the vaccine; second, MVA-B induces broad HIV-1-specific T 518 
cell responses, comprising of both CD4 and CD8 T cells, which were balanced after the 519 
third dose; third, the HIV-1-specific immune responses triggered by MVA-B were 520 
polyfunctional; fourth, MVA-B responses were maintained at least for one year in 85% 521 
of  vaccinees, with HIV-1-specific memory T cells being of TEM and TEMRA 522 
phenotypes for CD8+ T cells; fifth, the anti-vector responses were largely 523 
polyfunctional with predominance of memory CD8+ T cells of TEMRA phenotype. 524 
This immune profile fulfils immune requirements as a promissing HIV/AIDS vaccine 525 
candidate, and support to move forward the MVA-B product into larger clinical trial, 526 
alone or combined with other HIV-1 immunogens, like DNA or proteins. Undoubtedly, 527 
the immune value of MVA-B vaccine to impact the outcome of HIV-1 infection can 528 
only be tested in an efficacy trial.   529 
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727 
Figure Legends 728 
Figure 1: MVA-B-induced HIV-1-specific T cell responses across the study. (A) 729 
Chronological diagram showing the vaccination schedule followed in the RISVAC02 730 
study and the immunogenicity endpoints. (B) Percentage of responders at the different 731 
time points. The percentage of responders was calculated on the basis of volunteers with 732 
a positive IFN-γ ICS. (C) Magnitude of vaccine specific CD4+ and CD8+ T cells at the 733 
different time points. The mean values for the total responses (Env+Gag+GPN) in each 734 
T cell population are shown. The box plots showed the distribution of responses in 735 
positive responders only. The box indicated the median (solid line), mean (dash line), 736 
and interquartile range (IQR). p values for significant differences were determined using 737 
Mann-Whitney U test and are represented. (D) Breadth of CD4+ and CD8+ T cell 738 
responses at the different time points. Percentage of responders that recognized 1, 2 or 3 739 
HIV-1 peptide pools in both T cell subsets are shown. (E) Percentage of CD4+ and 740 
CD8+ T cells producing IFN-γ in response to Env, Gag or GPN peptide pools as 741 
measured by ICS at the different time points. The box plots showed the distribution of 742 
responses in positive responders only. The box indicated the median (solid line), mean 743 
(dash line), and interquartile range (IQR). p values for significant differences were 744 
determined using Wilcoxon rank sum test with continuity correction and are 745 
represented. All data are background substracted.  746 
 747 
Figure 2: Vaccine-induced T cell responses at primary immunogenicity endpoints 748 
(weeks 6 and 18). (A) Magnitude of HIV-1-specific CD4+ and CD8+ T cells after two 749 
and three doses of MVA-B. The mean values for the total responses (Env+Gag+GPN) 750 
in each T cell population are shown. The box plots showed the distribution of responses 751 
in positive responders only. The box indicated the median (solid line), mean (dash line), 752 
and interquartile range (IQR). (B) Percentages of HIV-1-specific T cells secreting 753 
cytokines in the CD4 and CD8 T subsets. The box plots showed the distribution of 754 
responses in positive responders only. The box indicated the median (solid line), mean 755 
(dash line), and interquartile range (IQR). Data points represent the sum of the 756 
frequencies obtained against Env+Gag+GPN peptide pools. All data are background 757 
substracted. ** represents p values<0.005 determined using Wilcoxon rank sum test 758 
with continuity correction comparing at the same time points the secretion of the 759 
different cytokines.  760 
 761 
Figure 3: Functional profile of vaccine-induced CD4 and CD8 T cells. The results 762 
shown are generated from the determinations in responders at weeks 6 and 18. All the 763 
possible combinations of the responses are shown on the x axis, whereas the percentage 764 
of the functionally distinct cell populations within the total CD4 and CD8 T cell 765 
populations are shown on the y axis. Responses are grouped and colour-coded on the 766 
basis of the number of functions. The bars correspond to the individual data point and 767 
interquartile range (IQR) after 2 (W6) or 3 (W18) doses of MVA-B. The pie charts 768 
showed the average proportion of the CD4 or CD8 vaccine-specific T cell responses 769 
according to the functions. 770 
 771 
Figure 4: Phenotype of long-lived memory vaccine-induced T cell responses. (A) 772 
Distribution of HIV-1 antigen-specific T cells at week 48 based on CCR7 expression in 773 
combination with CD45RA. The bars correspond to the individual data point and 774 
interquartile range (IQR) of the CD4+ and CD8+ T cell responses against 775 
Env+Gag+GPN with phenotype central memory (TCM: CD45RA−CCR7+), effector 776 
memory (TEM: CD45RA−CCR7−) or terminally differentiated effector memory 777 
(TEMRA: CD45RA+CCR7-). The pie charts showed the average proportion of the 778 
CD4+ or CD8+ vaccine-specific T cell responses according to the memory phenotype. * 779 
represent distributions that are different from the CD4 T cell subset at p<0.05 (Student 780 
T test). All data are background substracted. (B) Representative phenotypic profiles of 781 
long-lived memory HIV-1-specific CD4 and CD8 T cells. Fresh PBMCs obtained from 782 
the responder volunteers at week 48 were stimulated with Env, Gag or GPN peptide 783 
pools. The red dots indicate antigen-specific (IL-2 plus IFN-γ) vaccine-induced CD4+ T 784 
cells and blue dots indicate antigen-specific (IL-2 plus IFN-γ) vaccine-induced CD8+ T 785 
cells, both overlaid on the total T cell subsets (grey). Neg, background values in 786 
unstimulated cells. 787 
 788 
Figure 5: Anti-vector-induced T cell responses across the study. (A) Percentage of 789 
CD4+ and CD8+ T cells producing IFN-γ against MVA-infected cells as measured by 790 
ICS at the different time points. The box plots showed the distribution of responses in 791 
positive responders at weeks 6 and 18. The box indicated the median (solid line), mean 792 
(dash line), and interquartile range (IQR). All data are background substracted. p values 793 
for significant differences were determined using Wilcoxon rank sum test with 794 
continuity correction and are represented. (B) Functional profile of MVA-specific CD8 795 
T cells. The results shown are generated from the determinations in all the responders. 796 
All the possible combinations of the responses are shown on the x axis, whereas the 797 
percentages of the functionally distinct cell populations within the total CD8 T cell 798 
populations are shown on the y axis. Responses are grouped and colour-coded on the 799 
basis of the number of functions. The bars correspond to the individual data point and 800 
interquartile range (IQR) after 2 (W6) or 3 (W18) doses of MVA-B. The pie charts 801 
showed the average proportion of the MVA-specific CD8+ T cell responses according 802 
to the functions. (C) Phenotype of long-lived memory MVA-specific T cell responses. 803 
Distribution of MVA-specific T cells at week 48 based on CCR7 expression in 804 
combination with CD45RA. The bars correspond to the individual data point and 805 
interquartile range (IQR) of the CD4+ and CD8+ T cell responses against MVA-806 
infected cells with phenotype central memory (TCM: CD45RA−CCR7+), effector 807 
memory (TEM: CD45RA−CCR7−) or terminal effector memory (TEMRA: 808 
CD45RA+CCR7-). The pie charts showed the average proportion of the CD4+ or CD8+ 809 
MVA-specific T cell responses according to the memory phenotype. * represent 810 
distributions that are different from the CD4 T cell subset at p<0.05 (Student T test). All 811 
data are background substracted. 812 
TABLE 1: Vaccine responsiveness based on IFN-γ+ ICS assay across the RISVAC02 study 
 
 
 
An ICS was considered positive if the percentages of IFN-γ+ cells in the stimulated samples were 3 
times over the values obtained in the unstimulated controls and if the background-substracted 
magnitudes were higher than 0.02%. One volunteer at week 6 did not have data. Cumulative analysis 
represents a positive response at any time point post-vaccination. 
++One placebo recipient was excluded for the cumulative analysis due to the reactivity against GPN 
pool at baseline and at subsequent time points. For this reason, the GPN pool was excluded in the 
comparison of the cumulative responses between vaccinees and placebo groups. 
* The differences among cumulative proportions between vaccinees and placebo groups have been 
tested by comparing two binomial distributions (implemented by the R function prop. test). 
Vaccination 
group Antigen 
Week 6 
(2 Wks post 2nd) 
Week 18 
(2 Wks post 3rd) 
Week 48 
(30 Wks post 3rd) 
Cumulative 
(Any post vacc) 
CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8 
MVA-B 
(108 PFU) 
Env 7/12 (58.3%) 
4/12 
(33.3%) 
3/13 
(23.1%) 
5/13 
(38.5%) 
5/13 
(38.5%) 
5/13 
(38.5%) 
9/13 
(69.2%)
8/13 
(61.5%) 
Gag 1/12  (8.3%) 
3/12 
(25.0%) 
0/13  
(0%) 
5/13 
(38.5%) 
1/13  
(7.7%) 
6/13 
(46.1%) 
2/13 
(15.4%)
9/13 
(69.2%) 
GPN 0/12 (0%) 
3/12 
(25.0%) 
0/13  
(0%) 
4/13 
(30.8%) 
1/13  
(7.7%) 
5/13 
(38.5%) 
1/13 
(7.7%) 
9/13 
(69.2%) 
Any 7/12 (58.3%) 
6/12 
(50.0%)
3/13 
(23.1%)
8/13 
(61.5%)
5/13 
(38.5%)
9/13 
(69.2%) 
9/13 
(69.2%)
12/13 
(92.3%)*
Placebo 
Env 0/3 (0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
Gag 0/3 (0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
GPN 1/3++ (33.3%) 
1/3++ 
(33.3%) 
0/3 
(0%) 
0/3 
(0%) 
1/3++ 
(33.3%) 
0/3 
(0%) 
1/3++ 
(33.3%) 
1/3++ 
(33.3%) 
Any 0/3 (0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
0/3 
(0%) 
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